Optimization and mechanistic studies of psammaplin A type antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA)

Chemistry - A European Journal

Volumn 7, Issue 19, 2001, Pages 4296-4310

  Nicolaou, K C ^a,b   Hughes, Robert ^b   Pfefferkorn, Jeffrey A ^b   Barluenga, Sofia ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Antibiotics; Chemical biology; Combinatorial synthesis; Psammaplin A; Total synthesis

Indexed keywords

LEAD COMPOUNDS; SYNTHESIS (CHEMICAL);

ANTIBACTERIAL AGENTS;

SULFUR COMPOUNDS;

ANTI INFECTIVE AGENTS; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; DISULFIDE; OXIME; PSAMMAPLIN A; TYROSINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CHEMISTRY; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DIMERIZATION; DISULFIDES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OXIMES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 0035477708     PISSN: 09476539     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-3765(20011001)7:19<4296::AID-CHEM4296>3.0.CO;2-2     Document Type: Article

References (28)

1. K. C. Nicolaou, R. Hughes, J. A. Pfefferkorn, S. Barluenga, A. J. Roecker, Chem. Eur. J. 2001, 7, 4280-4295, preceding manuscript.
2. a) E. Quin̄oà, P. Crews, Tetrahedron Lett. 1987, 28, 3229-3232;
3. b) L. Arabshahi, F. J. Schmitz, J. Org. Chem. 1987, 52, 3584-3586.
4. For selected references regarding the emergence of resistance to antibiotics, see: a) D. van der Waaij, C. E. Nord, Int. J. Antimicrob. Agents 2000, 16, 191-197;
5. b) A. Virk, J. M. Steckelberg, Mayo Clin. Proc. 2000, 75, 200-214;
6. c) S. Stefani, A. Agodi, Int. J. Antimicrob. Agents 2000, 13, 143-153;
7. d) S. Mendez-Alvarez, X. Perez-Hernandez, F. Claverie-Martin, Int. Microbiol. 2000, 3, 71-80;
8. e) K. C. Nicolaou, C. N. C. Boddy, Sci. Am. 2001, May, 54-61.
9. See Figure 1, lower panel, for heterodimer nomenclature convention utilized in this manuscript.
10. J. Porter, J. Dykert, J. Rivier, Int. J. Peptide Protein Res. 1987, 30, 13-21.
11. 50 values for cytotoxicity were determined using a MTT cell proliferation assay, see; S. O'Hare, C. K. Atterwill, Methods in Molecular Biology, Vol 43: In vitro toxicity testing protocols, Humana Press, Totowa, N.J., 1995.
12. J. G. Hardman, L. E. Limbird, The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 1996.
13. Estimated log values were calculated using Log P Calculator v 4.5 available from Advanced Chemistry Development Inc.
14. D. Kim, I. S. Lee, J. H. Jung, S.-I. Yang, Arch. Pharm. Res. 1999, 22, 25-29.
15. For reviews, see: a) R. J. Recce, A. Maxwell, Crit. Rev. Biochem. Mol. Biol. 1991, 26, 335-375;
16. b) R. Menzel, M. Gellbert, Adv. Pharmacol. 1994, 29A, 39-69.
17. O. K. Kim, Exp. Opin. Ther. Patents 1998, 8, 959-969.
18. a) A. Maxwell, Mol. Microbiol. 1993, 9, 681-686;
19. b) N. Nakada, H. Shimada, T. Hirata, Y. Aoki, T. Kamiyama, J. Watanabe, M. Arisawa, Antimicrob. Agents Chemother. 1993, 37, 2656-2661.
20. H. J. Boehm, M. Boehringer, D. Bur, H. Gmuender, W. Huber, W. Klaus, D. Kostrewa, H. Kuehne, T. Luebbers, N. Meunier-Keller, F. Mueller, J. Med. Chem. 2000, 43, 2664-2674.
21. The authors have suggested a possible alternative explanation for the discrepancy between the level of gyrase inhibition and antibacterial potency by proposing that psammaplin A also acts on topoisomerase IV albeit in the absence of experimental data.
22. 50 values are 1000 to 10 000-fold higher than the observed MIC value for psammaplin A, it is unlikely that either of these enzymes represents this natural product's primary site of action.
23. For a review on disulfide toxicity, see R. Munday, Free Radical Biol. Med. 1989, 7, 659-673.
24. a) R. Munday, J. Appl. Toxicol. 1985, 5, 402-408;
25. b) R. Munday, J. Appl. Toxicol. 1985, 5, 409-413;
26. c) R. Munday, J. Appl. Toxicol. 1985, 5, 414-417.
27. a) See M. Knoll, F. Arenzana-Seisdedos, F. Bacelerie, D. Thomas, B. Friguet, M. Conconi, Chem. Biol. 1999, 6, 689-698 and references therein;
28. b) for a review, see: P. Waring, R. D. Eichner, A. Müllbacher, Med. Res. Rev. 1988, 8, 499-524.